Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 8-K (Current Report)
Report Date: November 2, 2023
Event Date: October 30, 2023 (Agreement) / November 2, 2023 (Closing)
Context: The Company, an emerging growth company, entered into a Securities Purchase Agreement with an institutional investor for a private placement of equity securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $4,000,003.44
- Net Proceeds: Approximately $3.5 million (after deducting placement agent fees and estimated offering expenses).
- Securities Issued:
- 980,393 shares of Common Stock (or Pre-Funded Warrants) at $4.08 per share.
- Series A Warrant: 5-year term to purchase up to 980,393 shares at $3.83 per share.
- Series B Warrant: 18-month term to purchase up to 980,393 shares at $3.83 per share.
- Placement Agent Fees: 7.0% of gross proceeds plus up to $60,000 in legal expense reimbursement and a $25,000 non-accountable expense allowance.
- Use of Proceeds: General working capital and general corporate purposes.
Material Changes and Agreements
Amendment to Existing Warrant: The Company amended an existing warrant issued in January 2023 (originally for 266,667 shares at $30.00 per share, expiring July 5, 2028). The amendment:
- Reduced the exercise price to $3.83 per share.
- Extended the expiration date to November 2, 2028.
- Restated the "Black Scholes Value" definition to eliminate an embedded derivative liability.
Registration Rights: The Company agreed to file a registration statement for the resale of the new shares and warrant shares within 20 days of closing, with effectiveness required by December 12, 2023 (or 60 days if subject to SEC review). Failure to meet deadlines may result in penalties up to 10.5% of gross proceeds.
Outlook, Risks, and Contingencies
- Dilution Protection: The new Warrants contain customary stock-based anti-dilution protection and beneficial ownership limitations (waivable with 61 days' notice).
- Penalty Risk: The Company faces potential liquidated damages of up to 10.5% of gross proceeds if registration statement filing or effectiveness deadlines are missed.
- Future Issuance Restrictions: The Purchase Agreement includes restrictions on future issuances of Company capital stock.
- Accounting Impact: The amendment to the January 2023 Warrant was specifically structured to eliminate an embedded derivative liability.
Investor Verification Checklist
- Verify the exact net proceeds received after all fees and expenses are finalized.
- Confirm the filing and effectiveness date of the registration statement to assess potential penalty exposure.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific restrictions on future capital raises.
- Monitor the Company's cash burn rate relative to the $3.5 million net proceeds to gauge runway extension.
- Check subsequent filings for the impact of the warrant amendment on the Company's balance sheet (derivative liability removal).